Our Research Team in the NEWS
Penn I3 Presentations at DDW 2024 Convention:
|
Mo1830 examining the need for washout periods when switching a patients biologic therapy. The work showed that we do not need full biologic washouts to decrease infection risk when moving to new therapies in IBD treatments.
|
|
Poster on impact of GLP1 agonist on inflammatory biomarkers in patients with IBD. Statistically significant decrease in CRP from baseline to 3 months on GLP1 therapy.
Collaboration spearheaded by @KHamiltonPhD with help from http://wwwi3study.org that determined epithelial pathogenesis in CD allowing greater disease understanding & potential new therapeutic targets
|
Tu1843 & Tu1844 multi-center PREVENT COVID work showing: -patients with IBD have sustained effectiveness of the COVID19 vaccination and vaccine titers dont correlate with COVID19 risk in IBD |
|
MILESTONE-IBD is a national year-long educational program for Advanced IBD fellows across the country. They had their graduation reception at DDW! Congrats on their Graduation. They are the future of IBD care!
